Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,15907602,pKa1,Piroxicam can be ionized as a zwitterion that has two pKa values (pKa1=1.86 and pKa2=5.46).,Enhanced bioavailability of piroxicam via salt formation with ethanolamines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907602/),,1.86,11357,DB00469,Tenoxicam
,15907602,pKa2,Piroxicam can be ionized as a zwitterion that has two pKa values (pKa1=1.86 and pKa2=5.46).,Enhanced bioavailability of piroxicam via salt formation with ethanolamines. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907602/),,5.46,11358,DB00469,Tenoxicam
,22495465,detection limit,The linear range of the plasma concentration was 1-16 μg/mL with a detection limit of 158 ng/mL.,Enhancement of the dissolution profile of Tenoxicam by a solid dispersion technique and its analytical evaluation using HPLC. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22495465/),[ng] / [ml],158,22166,DB00469,Tenoxicam
,2053921,elimination half-life,Tenoxicam is a nonsteroidal antiinflammatory drug with an elimination half-life of 60-80 hours; it is administered once daily.,The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),h,60-80,33905,DB00469,Tenoxicam
,2053921,steady-state concentrations,"The mean +/- SD steady-state concentrations in synovial fluid and plasma were 3.9 +/- 1.8 micrograms/ml and 9.2 +/- 3.7 micrograms/ml, respectively, yielding a mean +/- SD synovial fluid: plasma ratio of 0.43 +/- 0.12.",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),[μg] / [ml],3.9,33906,DB00469,Tenoxicam
,2053921,steady-state concentrations,"The mean +/- SD steady-state concentrations in synovial fluid and plasma were 3.9 +/- 1.8 micrograms/ml and 9.2 +/- 3.7 micrograms/ml, respectively, yielding a mean +/- SD synovial fluid: plasma ratio of 0.43 +/- 0.12.",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),[μg] / [ml],9.2,33907,DB00469,Tenoxicam
,2053921,synovial fluid: plasma ratio,"The mean +/- SD steady-state concentrations in synovial fluid and plasma were 3.9 +/- 1.8 micrograms/ml and 9.2 +/- 3.7 micrograms/ml, respectively, yielding a mean +/- SD synovial fluid: plasma ratio of 0.43 +/- 0.12.",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),,0.43,33908,DB00469,Tenoxicam
,2053921,synovial fluid:plasma ratio,"The synovial fluid:plasma ratio of unbound tenoxicam was 0.90 +/- 0.3 (95% confidence interval 0.68-1.11), which was not significantly different from a value of 1 (t = -1.09, P = 0.31).",The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2053921/),,0.90,33909,DB00469,Tenoxicam
,6336292,plasma clearance,The plasma clearance was low with values ranging from 1.3 to 4.2 ml/min and the volume of distribution Vss was small averaging at 20 to 40% of the total body weight.,Pharmacokinetics of tenoxicam in healthy human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),[ml] / [min],1.3 to 4.2,41326,DB00469,Tenoxicam
,6336292,half-life of elimination from the body,The median half-life of elimination from the body was found to be 72 hours (range 42 to 100 hours).,Pharmacokinetics of tenoxicam in healthy human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),h,72,41327,DB00469,Tenoxicam
exceeded,6336292,fraction bound,At pH 7.4 the fraction bound exceeded 99% but was highly dependent on the pH.,Pharmacokinetics of tenoxicam in healthy human volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),%,99,41328,DB00469,Tenoxicam
,6336292,maximum plasma levels,After oral administration of a 20-mg tablet complete and rapid absorption of the drug was observed with maximum plasma levels of 1.7 to 3.6 micrograms/ml reached within 0.5 to 2 hours.,Pharmacokinetics of tenoxicam in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6336292/),[μg] / [ml],1.7 to 3.6,41329,DB00469,Tenoxicam
,3329107,elimination half-life,The extraction ratio in the liver is small resulting in a long elimination half-life with a mean of 72 hours.,Overview on the pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3329107/),h,72,59113,DB00469,Tenoxicam
,3262939,unbound fractions of drug,"The unbound fractions of drug in synovial fluid and plasma were on average 0.015 and 0.011, respectively: not significantly different from each other.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),,0.015,66343,DB00469,Tenoxicam
,3262939,unbound fractions of drug,"The unbound fractions of drug in synovial fluid and plasma were on average 0.015 and 0.011, respectively: not significantly different from each other.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),,0.011,66344,DB00469,Tenoxicam
,3262939,peak concentrations,"The average peak concentrations of tenoxicam in plasma and synovial fluid were 4.3 and 1.4 micrograms/ml, respectively.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),[μg] / [ml],4.3,66345,DB00469,Tenoxicam
,3262939,peak concentrations,"The average peak concentrations of tenoxicam in plasma and synovial fluid were 4.3 and 1.4 micrograms/ml, respectively.",Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3262939/),[μg] / [ml],1.4,66346,DB00469,Tenoxicam
,8162655,elimination half-life,The elimination half-life varies between 30 and 70 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30 and 70,74980,DB00469,Tenoxicam
,8162655,oral bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,100,74981,DB00469,Tenoxicam
,8162655,bioavailability,The oral bioavailability of tenoxicam is 100% and rectal bioavailability is 80%.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),%,80,74982,DB00469,Tenoxicam
,8162655,elimination half-life,The mean elimination half-life is 60 to 75 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,60 to 75,74983,DB00469,Tenoxicam
,8162655,elimination half-life,The mean elimination half-life is 30 hours and does not appear to be affected by the age of the patient.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,30,74984,DB00469,Tenoxicam
,8162655,elimination half-life,Lornoxicam differs from other oxicam NSAIDs because it has a short elimination half-life of 3 to 4 hours.,Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8162655/),h,3 to 4,74985,DB00469,Tenoxicam
,8137596,Peak plasma concentrations,Peak plasma concentrations of 2.7 mg/L (range 2.3 to 3.0 mg/L) have been reported in different groups of fasted healthy volunteers 1.9 hours (1.0 to 5.0 hours) after a single oral dose of 20mg.,Clinical pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),[mg] / [l],2.7,75868,DB00469,Tenoxicam
,8137596,elimination half-life,A mean elimination half-life of 67 hours (49 to 81 hours) has been estimated.,Clinical pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),h,67,75869,DB00469,Tenoxicam
,8137596,apparent volume of distribution,"A small apparent volume of distribution of 9.6L (7.5 to 11.5L), and low total plasma clearance of 0.106 L/h (0.079 to 0.142 L/h), have been reported in different groups of healthy volunteers after oral and intravenous administration.",Clinical pharmacokinetics of tenoxicam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),l,9.6,75870,DB00469,Tenoxicam
,8137596,total plasma clearance,"A small apparent volume of distribution of 9.6L (7.5 to 11.5L), and low total plasma clearance of 0.106 L/h (0.079 to 0.142 L/h), have been reported in different groups of healthy volunteers after oral and intravenous administration.",Clinical pharmacokinetics of tenoxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137596/),[l] / [h],0.106,75871,DB00469,Tenoxicam
,3877538,half-life,"However, the mean half-life for synovial fluid (45 h) was not significantly different from that for plasma (42 h).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877538/),h,45,92345,DB00469,Tenoxicam
,3877538,half-life,"However, the mean half-life for synovial fluid (45 h) was not significantly different from that for plasma (42 h).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877538/),h,42,92346,DB00469,Tenoxicam
,2625372,Cmax,Cmax in the cirrhotic patients was 2.63 micrograms/ml (s.d. = 0.92) and tmax was 2.5 h (s.d. = 0.8).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),[μg] / [ml],2.63,93509,DB00469,Tenoxicam
,2625372,tmax,Cmax in the cirrhotic patients was 2.63 micrograms/ml (s.d. = 0.92) and tmax was 2.5 h (s.d. = 0.8).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),h,2.5,93510,DB00469,Tenoxicam
,2625372,elimination half-life (t1/2),The elimination half-life (t1/2) was 53.0 h (s.d. = 19.0) in the cirrhotic patients and 69.2 h (s.d. = 19.3) in the controls.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),h,53.0,93511,DB00469,Tenoxicam
,2625372,elimination half-life (t1/2),The elimination half-life (t1/2) was 53.0 h (s.d. = 19.0) in the cirrhotic patients and 69.2 h (s.d. = 19.3) in the controls.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),h,69.2,93512,DB00469,Tenoxicam
,2625372,Area under curve,Area under curve was significantly (p less than 0.05) smaller in the cirrhotic patients (159 micrograms.h/ml; s.d. = 65) than in the controls (254 micrograms.h/ml; s.d. = 92).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),[h·μg] / [ml],159,93513,DB00469,Tenoxicam
,2625372,Area under curve,Area under curve was significantly (p less than 0.05) smaller in the cirrhotic patients (159 micrograms.h/ml; s.d. = 65) than in the controls (254 micrograms.h/ml; s.d. = 92).,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),[h·μg] / [ml],254,93514,DB00469,Tenoxicam
,2625372,urinary excretion,The urinary excretion of the 5'-hydroxy metabolite of tenoxicam averaged 21.6% (s.d. = 3.8) of the administered dose in the cirrhotic patients and 22.1% (s.d. = 3.1) in the control subjects.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,21.6,93515,DB00469,Tenoxicam
,2625372,urinary excretion,The urinary excretion of the 5'-hydroxy metabolite of tenoxicam averaged 21.6% (s.d. = 3.8) of the administered dose in the cirrhotic patients and 22.1% (s.d. = 3.1) in the control subjects.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,22.1,93516,DB00469,Tenoxicam
,2625372,unbound drug fraction,The unbound drug fraction averaged 0.8% (s.d. = 0.3) in the cirrhotic patients and 0.8% (s.d. = 0.1) in the 12 control subjects who contributed data to this portion of the study.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,0.8,93517,DB00469,Tenoxicam
,2625372,unbound drug fraction,The unbound drug fraction averaged 0.8% (s.d. = 0.3) in the cirrhotic patients and 0.8% (s.d. = 0.1) in the 12 control subjects who contributed data to this portion of the study.,Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625372/),%,0.8,93518,DB00469,Tenoxicam
,7589053,terminal phase elimination half-life,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),h,19.5,96473,DB00469,Tenoxicam
,7589053,terminal phase elimination half-life,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),h,12.7,96474,DB00469,Tenoxicam
,7589053,clearance,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),[l] / [h],0.426,96475,DB00469,Tenoxicam
,7589053,clearance,The mean terminal phase elimination half-life was reduced from 19.5 h to 12.7 h due to an increase in clearance of the drug (0.426 vs 0.636 l.h-1).,"The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589053/),[l] / [h],0.636,96476,DB00469,Tenoxicam
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,45,101536,DB00469,Tenoxicam
,3317799,half-life,A pharmacokinetic study showed a half-life for tenoxicam of 45 h in synovial fluid when the half-life was 42 h in plasma.,Clinical experience with tenoxicam: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),h,42,101537,DB00469,Tenoxicam
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],2.6,101538,DB00469,Tenoxicam
,3317799,peak plasma levels,A single and multiple oral dose pharmacokinetic study of tenoxicam in the elderly showed no progressive accumulation with peak plasma levels of 2.6 micrograms/ml after the single dose and 12.4 micrograms/ml at steady state.,Clinical experience with tenoxicam: a review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3317799/),[μg] / [ml],12.4,101539,DB00469,Tenoxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,50.3,105018,DB00469,Tenoxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,28.1,105019,DB00469,Tenoxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,73.6,105020,DB00469,Tenoxicam
,2373127,t 1/2,"Cholestyramine increased piroxicam & tenoxicam elimination approximately 2-fold (t 1/2 50.3 vs 28.1 h and 73.6 vs 35.8 h, respectively).",Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373127/),h,35.8,105021,DB00469,Tenoxicam
,8894512,"""","The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],19.8,111072,DB00469,Tenoxicam
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],19.8,111073,DB00469,Tenoxicam
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],9.6,111074,DB00469,Tenoxicam
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],32.5,111075,DB00469,Tenoxicam
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],133.6,111076,DB00469,Tenoxicam
,8894512,lymphatic clearance,"The ""lymphatic clearance"" differed substantially between the investigated compounds (mean +/- SD: R-ibuprofen, 19.8 +/- 9.4; S-ibuprofen, 9.6 +/- 3.6; tenoxicam, 32.5 +/- 31.3; nabumetone, 133.6 +/- 75.2; 6MNA, 18.3 +/- 8.5 microliters/min/kg).",Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),[μl] / [kg·min],18.3,111077,DB00469,Tenoxicam
not exceed,8894512,Overall recovery,Overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Transfer of different nonsteroidal antiinflammatory drugs via the lymphatic system in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894512/),%,5,111078,DB00469,Tenoxicam
,6342955,half-life,"Plasma concentrations of tilcotil showed that the drug's half-life was approximately 50 hours, compatible with once daily dosage, and steady state concentrations on multiple dosing were reached after 10 to 12 days.",Gastro-intestinal blood loss with high dose tilcotil (Ro 12-0068) and aspirin: an open crossover clinical trial and pharmacokinetic assessment in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342955/),h,50,114992,DB00469,Tenoxicam
,1361533,unbound fraction,"As a result of this decrease, the unbound fraction of tenoxicam in uraemic rats (0.06 +/- 0.02) and in anephric rats (0.11 +/- 0.08) increased with respect to the control group (0.03 +/- 0.004).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.06,119684,DB00469,Tenoxicam
,1361533,unbound fraction,"As a result of this decrease, the unbound fraction of tenoxicam in uraemic rats (0.06 +/- 0.02) and in anephric rats (0.11 +/- 0.08) increased with respect to the control group (0.03 +/- 0.004).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.11,119685,DB00469,Tenoxicam
,1361533,unbound fraction,"As a result of this decrease, the unbound fraction of tenoxicam in uraemic rats (0.06 +/- 0.02) and in anephric rats (0.11 +/- 0.08) increased with respect to the control group (0.03 +/- 0.004).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.03,119686,DB00469,Tenoxicam
,1361533,Vdss,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),ml,55,119687,DB00469,Tenoxicam
,1361533,Vdss,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),ml,69,119688,DB00469,Tenoxicam
,1361533,Vdss,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),ml,96,119689,DB00469,Tenoxicam
,1361533,CL,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],7,119690,DB00469,Tenoxicam
,1361533,CL,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],12,119691,DB00469,Tenoxicam
,1361533,CL,Both plasma clearance (CL) and apparent volume of distribution at steady-state (Vdss) rose significantly with the increase in the unbound fraction: (Vdss 55 +/- 6 mL (control rats); 69 +/- 12 mL (uraemic rats); 96 +/- 30 mL (anephric rats); CL = 7 +/- 1 mL h-1 (control rats); 12 +/- 4 mL h-1 (uraemic rats); 15 +/- 7 mL h-1 (anephric rats)).,Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],15,119692,DB00469,Tenoxicam
less,1361533,extraction ratio,"Tenoxicam elimination was found to be restrictive, with an extraction ratio less than 0.1 in the three groups.",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),,0.1,119693,DB00469,Tenoxicam
,1361533,intrinsic clearance,"The induction of nephrotic syndrome was observed to have a significant effect on intrinsic metabolic activity, intrinsic clearance of tenoxicam being reduced by 30% in the anephric rats (161 +/- 38 mL h-1) with respect to the values obtained in the control group (228 +/- 22 mL h-1).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],161,119694,DB00469,Tenoxicam
,1361533,intrinsic clearance,"The induction of nephrotic syndrome was observed to have a significant effect on intrinsic metabolic activity, intrinsic clearance of tenoxicam being reduced by 30% in the anephric rats (161 +/- 38 mL h-1) with respect to the values obtained in the control group (228 +/- 22 mL h-1).",Effect of uraemia and anephric state on the pharmacokinetics of tenoxicam in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361533/),[ml] / [h],228,119695,DB00469,Tenoxicam
,7986242,Cmax,"Plasma peak concentrations appeared highest after the commercial tablet (mean +/- SD: Cmax 2.8 +/- 0.55 mg/l), but the difference to the effervescent tablet (2.7 +/- 0.41 mg/l) and the milk formulation (2.5 +/- 0.41 mg/l) was negligible.",Relative bioavailability of oral dosage forms of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),[mg] / [l],2.8,121929,DB00469,Tenoxicam
,7986242,Cmax,"Plasma peak concentrations appeared highest after the commercial tablet (mean +/- SD: Cmax 2.8 +/- 0.55 mg/l), but the difference to the effervescent tablet (2.7 +/- 0.41 mg/l) and the milk formulation (2.5 +/- 0.41 mg/l) was negligible.",Relative bioavailability of oral dosage forms of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),[mg] / [l],2.7,121930,DB00469,Tenoxicam
,7986242,Cmax,"Plasma peak concentrations appeared highest after the commercial tablet (mean +/- SD: Cmax 2.8 +/- 0.55 mg/l), but the difference to the effervescent tablet (2.7 +/- 0.41 mg/l) and the milk formulation (2.5 +/- 0.41 mg/l) was negligible.",Relative bioavailability of oral dosage forms of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),[mg] / [l],2.5,121931,DB00469,Tenoxicam
,7986242,elimination half-lives,"Similar mean elimination half-lives of 73, 77, and 77 h were obtained with the effervescent tablet, the milk drink, and the commercial tablet, respectively.",Relative bioavailability of oral dosage forms of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),h,73,121932,DB00469,Tenoxicam
,7986242,elimination half-lives,"Similar mean elimination half-lives of 73, 77, and 77 h were obtained with the effervescent tablet, the milk drink, and the commercial tablet, respectively.",Relative bioavailability of oral dosage forms of tenoxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),h,77,121933,DB00469,Tenoxicam
,7986242,bioavailability,Average bioavailability relative to the tablet was for the effervescent tablet and for the milk drink 96% with a coefficient of variation of 8%.,Relative bioavailability of oral dosage forms of tenoxicam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7986242/),%,96,121934,DB00469,Tenoxicam
,10445485,limit of detection (LOD),"The urinary tenoxicam limit of detection (LOD) and limit of quantitation (LOQ) were 0.3 and 0.4 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.3,123140,DB00469,Tenoxicam
,10445485,limit of quantitation (LOQ),"The urinary tenoxicam limit of detection (LOD) and limit of quantitation (LOQ) were 0.3 and 0.4 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.4,123141,DB00469,Tenoxicam
,10445485,LOD,"The urinary hydroxytenoxicam LOD and LOQ were 0.6 and 0.8 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.6,123142,DB00469,Tenoxicam
,10445485,LOQ,"The urinary hydroxytenoxicam LOD and LOQ were 0.6 and 0.8 microg/mL, respectively.",The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[μg] / [ml],0.8,123143,DB00469,Tenoxicam
,10445485,peak average concentration,The peak average concentration was 434.5 ng/mL at 3 h.,The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[ng] / [ml],434.5,123144,DB00469,Tenoxicam
,10445485,LOD,The serum tenoxicam LOD and LOQ were 5.7 and 7.3 ng/mL.,The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[ng] / [ml],5.7,123145,DB00469,Tenoxicam
,10445485,LOQ,The serum tenoxicam LOD and LOQ were 5.7 and 7.3 ng/mL.,The elimination profiles of tenoxicam and hydroxytenoxicam in equine urine and serum after a 200-mg oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445485/),[ng] / [ml],7.3,123146,DB00469,Tenoxicam
,15229460,area under the plasma concentration-time curve (AUC) from time 0 to infinity,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],190,123471,DB00469,Tenoxicam
,15229460,area under the plasma concentration-time curve (AUC) from time 0 to infinity,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],261,123472,DB00469,Tenoxicam
,15229460,area under the plasma concentration-time curve (AUC) from time 0 to infinity,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],335,123473,DB00469,Tenoxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[ml] / [h],113,123474,DB00469,Tenoxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[ml] / [h],77,123475,DB00469,Tenoxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],335,123476,DB00469,Tenoxicam
,15229460,oral clearance,"After a single dose of tenoxicam, the area under the plasma concentration-time curve (AUC) from time 0 to infinity and the oral clearance of tenoxicam were 190 +/- 48 microg x mL(-1) x h and 113 +/- 30 mL x h(-1), respectively, in wild-type homozygous subjects (CYP2C9*1/*1), as compared with 261 +/- 14 microg x mL(-1) x h (P = .013) and 77 +/- 4 mL x h(-1) (P = .036), respectively, in CYP2C9*1/*2 heterozygous subjects and 335 +/- 126 microg x mL(-1) x h (P = .003) and 67 +/- 23 mL x h(-1) (P = .008) in CYP2C9*1/*3, respectively, heterozygous subjects.",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[ml] / [h],67,123477,DB00469,Tenoxicam
,15229460,minimum plasma (trough) tenoxicam concentration (Cmin,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],5.2,123478,DB00469,Tenoxicam
,15229460,minimum plasma (trough) tenoxicam concentration (Cmin,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],7.6,123479,DB00469,Tenoxicam
,15229460,maximum tenoxicam plasma concentration (Cmax,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],7.4,123480,DB00469,Tenoxicam
,15229460,maximum tenoxicam plasma concentration (Cmax,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[μg] / [ml],10.5,123481,DB00469,Tenoxicam
,15229460,AUC,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],152,123482,DB00469,Tenoxicam
,15229460,AUC,"After 7 simulated daily doses, significant differences were observed between CYP2C9*1/*1 and CYP2C9*1/*3 individuals in relation to the minimum plasma (trough) tenoxicam concentration (Cmin, 5.2 +/- 1.3 microg x mL(-1) versus 7.6 +/- 2.6 microg x mL(-1); P = .021), maximum tenoxicam plasma concentration (Cmax, 7.4 +/- 1.9 microg x mL(-1) versus 10.5 +/- 3.0 microg x mL(-1); P = .020), and 24-hour AUC (152 +/- 39 microg x mL(-1) x h versus 219 +/- 72 microg x mL(-1) x h).",CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15229460/),[h·μg] / [ml],219,123483,DB00469,Tenoxicam
,8444358,time-to-peak,The tenoxicam kinetics in these ocular fluids followed that in plasma with the time-to-peak shifted to higher values in the vitreous (1 h) as compared to that in the aqueous and plasma (40 min).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),h,1,127768,DB00469,Tenoxicam
,8444358,time-to-peak,The tenoxicam kinetics in these ocular fluids followed that in plasma with the time-to-peak shifted to higher values in the vitreous (1 h) as compared to that in the aqueous and plasma (40 min).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),min,40,127769,DB00469,Tenoxicam
,8444358,AUC,AUC was also higher in the vitreous (10.4 micrograms.h/ml) than in the aqueous humor (2.8 micrograms.h/ml).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),[h·μg] / [ml],10.4,127770,DB00469,Tenoxicam
,8444358,AUC,AUC was also higher in the vitreous (10.4 micrograms.h/ml) than in the aqueous humor (2.8 micrograms.h/ml).,Intraocular and plasma kinetics of tenoxicam in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8444358/),[h·μg] / [ml],2.8,127771,DB00469,Tenoxicam
,19224373,solubility,"The volume ratio of 5:4:1 in the DMSO/polyethoxylated castor oil/ethanol system resulted in a more suitable vehicle than other systems, with a high solubility (20.73 mg/ml) and low viscosity (10.0 Cp).",Improving tenoxicam solubility and bioavailability by cosolvent system. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19224373/),[mg] / [ml],20.73,144017,DB00469,Tenoxicam
<,8024649,plasma clearances,"However, based on literature data for 18 non-steroidal anti-inflammatory drugs (NSAIDs) with low plasma clearances (< 60 ml/min), we have shown that most of these low-extraction compounds are non-restrictively eliminated, i.e. their hepatic extraction ratio exceeds their unbound fraction in plasma.",Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8024649/),[ml] / [min],60,146392,DB00469,Tenoxicam
,29638052,flow rate,The optimized flow rate of 1.0 mL/min provided proper separation of peaks and column clean up within 5 min.,DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[ml] / [min],1.0,148447,DB00469,Tenoxicam
,29638052,C.,The values of C. and area under curve for current study were 1.776 ± 0.003 pg/mL and 179.97 ± 0.0681 (mean ± SEM) pg x h/mL.,DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[pg] / [ml],1.776,148448,DB00469,Tenoxicam
,29638052,area under curve,The values of C. and area under curve for current study were 1.776 ± 0.003 pg/mL and 179.97 ± 0.0681 (mean ± SEM) pg x h/mL.,DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[h·pg] / [ml],179.97,148449,DB00469,Tenoxicam
,29638052,t,"The values of t, and volume of distribution for tenoxicam in current study were 74.103 0.167 h (mean ± SEM) and 11.962 ± 0.0677 L/kg (mean ± SEM), respectively.",DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),h,74.103,148450,DB00469,Tenoxicam
,29638052,volume of distribution,"The values of t, and volume of distribution for tenoxicam in current study were 74.103 0.167 h (mean ± SEM) and 11.962 ± 0.0677 L/kg (mean ± SEM), respectively.",DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),h,0.167,148451,DB00469,Tenoxicam
,29638052,volume of distribution,"The values of t, and volume of distribution for tenoxicam in current study were 74.103 0.167 h (mean ± SEM) and 11.962 ± 0.0677 L/kg (mean ± SEM), respectively.",DETERMINATION OF TENOXICAM IN THE PLASMA BY REVERSE PHASE HPLC METHOD USING SINGLE STEP EXTRACTION TECHNIQUE: A RELIABLE AND COST EFFECTIVE APPROACH. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29638052/),[l] / [kg],11.962,148452,DB00469,Tenoxicam
,3709612,areas under the plasma concentration-time curve,"The mean areas under the plasma concentration-time curve (138 +/- 53 micrograms/ml X h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam.",Pharmacokinetics of tenoxicam in patients with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709612/),[μg] / [h·ml],138,159033,DB00469,Tenoxicam
,3497039,clearance,"Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively.",Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3497039/),[l] / [h],0.096,174943,DB00469,Tenoxicam
,3497039,elimination half-life,"Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively.",Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3497039/),h,76,174944,DB00469,Tenoxicam
,3497039,apparent volume of distribution,"Model-independent analysis showed the clearance, elimination half-life and apparent volume of distribution to be independent of dose with mean values of 0.096 L/h, 76 h and 9.2 L respectively.",Pharmacokinetics of tenoxicam after oral administration in healthy human subjects of various single doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3497039/),l,9.2,174945,DB00469,Tenoxicam
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.39,178926,DB00469,Tenoxicam
,7899229,synovial fluid exit rate constant,"The single dose mean +/- S.D. synovial fluid exit rate constant for diclofenac was 0.39 +/- 0.33 hr-1 (n = 6), which was not significantly different from that determined by method 2; which was 0.49 +/- 0.52 hr-1.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.49,178927,DB00469,Tenoxicam
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178928,DB00469,Tenoxicam
,7899229,steady state mean,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178929,DB00469,Tenoxicam
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.43,178930,DB00469,Tenoxicam
,7899229,s,"The steady state mean +/- S.D. diclofenac synovial fluid exit rate constants for methods 1 and 2 were 0.43 +/- 0.18 and 0.54 +/- 0.71 hr-1 (n = 8), respectively, which were not significantly different.",Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7899229/),1/[h],0.54,178931,DB00469,Tenoxicam
,3723402,adsorption capacity,The Langmuir binding isotherms determined in buffer solutions at pH 7.5 indicated a much greater adsorption capacity of cholestyramine (1.63 g of drug per g of resin) than of charcoal (0.18 g/g of adsorbent) for the acidic drug with a pKa of 5.3.,Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),g,1.63,188465,DB00469,Tenoxicam
,3723402,adsorption capacity,The Langmuir binding isotherms determined in buffer solutions at pH 7.5 indicated a much greater adsorption capacity of cholestyramine (1.63 g of drug per g of resin) than of charcoal (0.18 g/g of adsorbent) for the acidic drug with a pKa of 5.3.,Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),[g] / [g],0.18,188466,DB00469,Tenoxicam
,3723402,pKa,The Langmuir binding isotherms determined in buffer solutions at pH 7.5 indicated a much greater adsorption capacity of cholestyramine (1.63 g of drug per g of resin) than of charcoal (0.18 g/g of adsorbent) for the acidic drug with a pKa of 5.3.,Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),,5.3,188467,DB00469,Tenoxicam
,3723402,total body clearance,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),[l] / [h],0.65,188468,DB00469,Tenoxicam
,3723402,total body clearance,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),[l] / [h],0.13,188469,DB00469,Tenoxicam
,3723402,elimination half-life,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),h,31 to 5.4,188470,DB00469,Tenoxicam
,3723402,mean residence time of drug,"Due to an increased total body clearance (0.65 vs. 0.13 liters/hr), the elimination half-life was reduced from a median base-line value of 31 to 5.4 hr and the mean residence time of drug in the body was decreased from 41 to 7.9 hr.",Acceleration of the elimination of tenoxicam by cholestyramine in the dog. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723402/),h,41,188471,DB00469,Tenoxicam
,11397584,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 2452.17+/-86.49 ng h/ml as compared to 1357.69+/-102.36 ng h/ml following intranasal dosing.,Intranasal delivery of tenoxicam in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397584/),[h·ng] / [ml],2452.17,190331,DB00469,Tenoxicam
,11397584,area under the plasma concentration curve,Following intravenous administration the area under the plasma concentration curve was 2452.17+/-86.49 ng h/ml as compared to 1357.69+/-102.36 ng h/ml following intranasal dosing.,Intranasal delivery of tenoxicam in rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397584/),[h·ng] / [ml],1357.69,190332,DB00469,Tenoxicam
,11397584,relative bioavailability,This corresponds to a relative bioavailability of 55.36%.,Intranasal delivery of tenoxicam in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11397584/),%,55.36,190333,DB00469,Tenoxicam
,8218966,F(abs),"The extent of absorption of intramuscularly administered tenoxicam was complete (mean +/- CV per cent: F(abs) 0.99 +/- 20 per cent) with no difference between the two extravascular administrations (F(rel) 0.95 +/- 10 per cent, intramuscular vs oral).",Bioavailability of intramuscularly administered tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),%,0.99,193708,DB00469,Tenoxicam
,8218966,F(rel),"The extent of absorption of intramuscularly administered tenoxicam was complete (mean +/- CV per cent: F(abs) 0.99 +/- 20 per cent) with no difference between the two extravascular administrations (F(rel) 0.95 +/- 10 per cent, intramuscular vs oral).",Bioavailability of intramuscularly administered tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),%,0.95,193709,DB00469,Tenoxicam
,8218966,Tmax,After intramuscular administration tenoxicam was more rapidly absorbed compared to the oral dose (Tmax 0.71 h +/- 80 per cent vs 1.4 h +/- 62 per cent; p > 0.05).,Bioavailability of intramuscularly administered tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),h,0.71,193710,DB00469,Tenoxicam
,8218966,Tmax,After intramuscular administration tenoxicam was more rapidly absorbed compared to the oral dose (Tmax 0.71 h +/- 80 per cent vs 1.4 h +/- 62 per cent; p > 0.05).,Bioavailability of intramuscularly administered tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),h,1.4,193711,DB00469,Tenoxicam
,8218966,Peak concentrations,Peak concentrations after oral and intramuscular administration (Cmax 2.5 mg l-1 +/- 19 per cent vs 2.7 mg l-1 +/- 14 per cent; p < 0.05) were very similar.,Bioavailability of intramuscularly administered tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),[mg] / [l],2.5,193712,DB00469,Tenoxicam
,8218966,Cmax,Peak concentrations after oral and intramuscular administration (Cmax 2.5 mg l-1 +/- 19 per cent vs 2.7 mg l-1 +/- 14 per cent; p < 0.05) were very similar.,Bioavailability of intramuscularly administered tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),[mg] / [l],2.5,193713,DB00469,Tenoxicam
,8218966,Cmax,Peak concentrations after oral and intramuscular administration (Cmax 2.5 mg l-1 +/- 19 per cent vs 2.7 mg l-1 +/- 14 per cent; p < 0.05) were very similar.,Bioavailability of intramuscularly administered tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218966/),[mg] / [l],2.7,193714,DB00469,Tenoxicam
,3879830,half-life,"However, the mean half-life for synovial fluid (45 hours) was not significantly different from that for plasma (42 hours).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879830/),h,45,200159,DB00469,Tenoxicam
,3879830,half-life,"However, the mean half-life for synovial fluid (45 hours) was not significantly different from that for plasma (42 hours).",A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879830/),h,42,200160,DB00469,Tenoxicam
,3499163,time taken to reach peak,5 Food lengthened the time taken to reach peak tenoxicam concentrations (5.82 +/- 4.6 vs 1.84 +/- 1.0 h in the fasting state; P less than 0.02) and marginally reduced the peak concentrations achieved.,Effect of food and various antacids on the absorption of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499163/),h,5.82,203346,DB00469,Tenoxicam
,3499163,time taken to reach peak,5 Food lengthened the time taken to reach peak tenoxicam concentrations (5.82 +/- 4.6 vs 1.84 +/- 1.0 h in the fasting state; P less than 0.02) and marginally reduced the peak concentrations achieved.,Effect of food and various antacids on the absorption of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499163/),h,1.84,203347,DB00469,Tenoxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.71,203929,DB00469,Tenoxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],3.24,203930,DB00469,Tenoxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],8.74,203931,DB00469,Tenoxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],46.05,203932,DB00469,Tenoxicam
,9167225,lymphatic clearance,"The ""lymphatic clearance"" substantially differed between the investigated compounds (mean +/- SD: R-ibuprofen 6.71 +/- 3.15 microliters/min, S-ibuprofen 3.24 +/- 1.20 microliters/min, tenoxicam 8.74 +/- 8.11 microliters/min, nabumetone 46.05 +/- 26.08 microliters/min and 6MNA 6.32 +/- 2.96 microliters/min).",Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),[μl] / [min],6.32,203933,DB00469,Tenoxicam
not exceed,9167225,overall recovery,The overall recovery of the investigated compounds in lymph did not exceed 5% of the doses given.,Lymph distribution of different non-steroidal anti-inflammatory drugs assessed by microsurgical cannulation of the thoracic duct in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9167225/),%,5,203934,DB00469,Tenoxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,31.9,208746,DB00469,Tenoxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,67.4,208747,DB00469,Tenoxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,28.1,208748,DB00469,Tenoxicam
,3260866,half-lives,The average values of half-lives were reduced (tenoxicam: 31.9 h vs 67.4 h; piroxicam: 28.1 h vs 46.8 h) due to increases in clearance.,The influence of cholestyramine on the elimination of tenoxicam and piroxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3260866/),h,46.8,208749,DB00469,Tenoxicam
,11881981,plasma elimination half-life,A positive correlation was found between an increase in the free fraction (% F) of tenoxicam in plasma and a decrease in the plasma elimination half-life in the low creatinine clearance group (40-20 ml/min.) both after the single-dose and at steady-state.,"Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881981/),[ml] / [min],40-20,213054,DB00469,Tenoxicam
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,1.2,214118,DB00469,Tenoxicam
,10640513,K(i),Lornoxicam 5'-hydroxylation was competitively inhibited in vitro by both phenprocoumon (K(i) = 1.2 +/- 0.4 microM) and acenocoumarol (K(i) = 5.5 +/- 3.5 microM).,Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10640513/),μM,5.5,214119,DB00469,Tenoxicam
,2788089,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h.,Plasma tenoxicam concentrations after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],2.76,214584,DB00469,Tenoxicam
,2788089,time to reach Cmax (Tmax),Maximum plasma concentration (Cmax) after the first dose was 2.76 +/- 0.48 micrograms/ml (mean +/- s.d.) and the time to reach Cmax (Tmax) was 5.0 +/- 3.0 h.,Plasma tenoxicam concentrations after single and multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,5.0,214585,DB00469,Tenoxicam
,2788089,area under the plasma concentration-time curve (AUC0-infinity),The area under the plasma concentration-time curve (AUC0-infinity) after a single administration of tenoxicam was 242.5 +/- 73.5 micrograms x h/ml.,Plasma tenoxicam concentrations after single and multiple oral doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[h·μg] / [ml],242.5,214586,DB00469,Tenoxicam
,2788089,elimination half-life (t1/2),The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml.,Plasma tenoxicam concentrations after single and multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,66.3,214587,DB00469,Tenoxicam
,2788089,plasma concentration at 24 hours after dosing (Cmin),The elimination half-life (t1/2) was 66.3 +/- 15.8 h and the plasma concentration at 24 hours after dosing (Cmin) was 1.84 +/- 0.33 micrograms/ml.,Plasma tenoxicam concentrations after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],1.84,214588,DB00469,Tenoxicam
,2788089,Cmax,"At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours.",Plasma tenoxicam concentrations after single and multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],13.63,214589,DB00469,Tenoxicam
,2788089,Tmax,"At steady-state, Cmax averaged 13.63 +/- 3.33 micrograms/ml and Tmax remained 5.0 +/- 3.0 hours.",Plasma tenoxicam concentrations after single and multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,5.0,214590,DB00469,Tenoxicam
,2788089,AUC within a dosing interval at steady-state,"AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h.",Plasma tenoxicam concentrations after single and multiple oral doses. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[h·μg] / [ml],262.2,214591,DB00469,Tenoxicam
,2788089,Cminss,"AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h.",Plasma tenoxicam concentrations after single and multiple oral doses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),[μg] / [ml],9.67,214592,DB00469,Tenoxicam
,2788089,t1/2,"AUC within a dosing interval at steady-state was 262.2 +/- 67.0 micrograms x h/ml, Cminss was 9.67 +/- 3.25 micrograms/ml, and t1/2 averaged 74.2 +/- 13.3 h.",Plasma tenoxicam concentrations after single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),h,74.2,214593,DB00469,Tenoxicam
,2788089,accumulation ratio,The average fluctuation during multiple-dose administration was 26.8 +/- 8.0% and the accumulation ratio was 5.82 +/- 0.60.,Plasma tenoxicam concentrations after single and multiple oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2788089/),,5.82,214594,DB00469,Tenoxicam
,3879481,time for peak plasma drug levels,"The rate of absorption was slower with post-prandial than with pre-prandial administration, resulting in a significantly later time for peak plasma drug levels (4.1 h compared to 1.3 h).",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,4.1,216231,DB00469,Tenoxicam
,3879481,time for peak plasma drug levels,"The rate of absorption was slower with post-prandial than with pre-prandial administration, resulting in a significantly later time for peak plasma drug levels (4.1 h compared to 1.3 h).",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,1.3,216232,DB00469,Tenoxicam
,3879481,t1/2,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,0.47,216233,DB00469,Tenoxicam
,3879481,t1/2,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,0.18,216234,DB00469,Tenoxicam
,3879481,peak time,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,4.7,216235,DB00469,Tenoxicam
,3879481,peak time,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),h,2.3,216236,DB00469,Tenoxicam
,3879481,peak level,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),[μg] / [ml],4.2,216237,DB00469,Tenoxicam
,3879481,peak level,"Similarly, the rate of absorption was significantly slower after concurrent antacid than without antacid (t1/2 0.47 h compared to 0.18 h) resulting in a later peak time (4.7 h compared to 2.3 h) and significantly lower peak level (4.2 micrograms X ml-1 compared to 5.1 micrograms X ml-1) of parent drug in plasma.",The effects of food and of antacid on the single oral dose pharmacokinetics of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879481/),[μg] / [ml],5.1,216238,DB00469,Tenoxicam
,17063980,retention time,"The retention time observed for meloxicam and tenoxicam (internal standard) was 1.8 and 1.4 minutes, respectively.",Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063980/),min,1.8,216288,DB00469,Tenoxicam
,17063980,retention time,"The retention time observed for meloxicam and tenoxicam (internal standard) was 1.8 and 1.4 minutes, respectively.",Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063980/),min,1.4,216289,DB00469,Tenoxicam
,17063980,recovery,The mean recovery of meloxicam was 95.9% and the limit ofquantification was 0.02 microg/ml.,Meloxicam determination in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS-MS) in Brazilian bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063980/),%,95.9,216290,DB00469,Tenoxicam
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,10.4,219117,DB00469,Tenoxicam
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,4.5,219118,DB00469,Tenoxicam
,8352822,flow rate,The flow rate was 1 ml/min and the effluent was monitored at 365 nm with 0.02 AUFS (absorbance units full scale).,"High-performance liquid chromatographic analysis of piroxicam and tenoxicam in plasma, blood and buffer solution. Application to pharmacokinetic studies in small laboratory animals. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352822/),[ml] / [min],1,220013,DB00469,Tenoxicam
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],2.8,246855,DB00469,Tenoxicam
,8148224,Cmax,"Cmax was increased significantly when tenoxicam was given with probenecid (2.8 micrograms ml-1 alone, 3.5 micrograms ml-1 after probenecid; P < 0.005).",Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148224/),[μg] / [ml],3.5,246856,DB00469,Tenoxicam
,3879831,peak plasma level,Approximately five-fold accumulation was found at steady-state (mean peak plasma level 2.6 micrograms/ml for a single dose against 12.4 micrograms/ml at steady-state).,Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879831/),[μg] / [ml],2.6,251149,DB00469,Tenoxicam
,3879831,peak plasma level,Approximately five-fold accumulation was found at steady-state (mean peak plasma level 2.6 micrograms/ml for a single dose against 12.4 micrograms/ml at steady-state).,Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879831/),[μg] / [ml],12.4,251150,DB00469,Tenoxicam
,3879831,plasma level at steady-state,Mean pre-dose plasma level at steady-state was 9.6 micrograms/ml with a coefficient of variation of 11%.,Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3879831/),[μg] / [ml],9.6,251151,DB00469,Tenoxicam
,18992346,AUC(0-infinity),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[h·μg] / [ml],256,252735,DB00469,Tenoxicam
,18992346,AUC(0-infinity),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[h·μg] / [ml],150,252736,DB00469,Tenoxicam
,18992346,AUC(0-infinity),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[h·μg] / [ml],169,252737,DB00469,Tenoxicam
,18992346,half-life time (t1/2),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),h,102,252738,DB00469,Tenoxicam
,18992346,half-life time (t1/2),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),h,56,252739,DB00469,Tenoxicam
,18992346,half-life time (t1/2),Significant increases were found in CYP2C9*3 alleles vs. *1 and *2 in AUC(0-infinity) (median (min-max)): 256 (230-516) vs. 150 (100-268) and 169 (124-197) microg h/mL (p<0.01) and half-life time (t1/2) 102 (79-36) vs. 56 (45-94) and 64 (60-80)h (p<0.01).,Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),h,64,252740,DB00469,Tenoxicam
,18992346,C(max),"Non-significant differences were observed in C(max) 1.9 (1.8-2.9) vs. 2.4 (1.7-3.4), 2.5 (1.6-2.9) microg/mL or in according to CYP2C8 alleles presence.",Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[μg] / [ml],1.9,252741,DB00469,Tenoxicam
,18992346,C(max),"Non-significant differences were observed in C(max) 1.9 (1.8-2.9) vs. 2.4 (1.7-3.4), 2.5 (1.6-2.9) microg/mL or in according to CYP2C8 alleles presence.",Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[μg] / [ml],2.4,252742,DB00469,Tenoxicam
,18992346,C(max),"Non-significant differences were observed in C(max) 1.9 (1.8-2.9) vs. 2.4 (1.7-3.4), 2.5 (1.6-2.9) microg/mL or in according to CYP2C8 alleles presence.",Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18992346/),[μg] / [ml],2.5,252743,DB00469,Tenoxicam
,1425878,half-life (t1/2),"After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL.f-1) of 4.3 ml.min-1, and an apparent volume of distribution (Vz.f-1) of 11.81.",The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),h,33,255615,DB00469,Tenoxicam
,1425878,apparent clearance (CL.f-1),"After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL.f-1) of 4.3 ml.min-1, and an apparent volume of distribution (Vz.f-1) of 11.81.",The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),[ml] / [min],4.3,255616,DB00469,Tenoxicam
,1425878,apparent volume of distribution (Vz.f-1),"After a single dose, tenoxicam had a half-life (t1/2) of 33 h, an apparent clearance (CL.f-1) of 4.3 ml.min-1, and an apparent volume of distribution (Vz.f-1) of 11.81.",The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),,11.81,255617,DB00469,Tenoxicam
,1425878,maximum tenoxicam concentration (Cmax),The maximum tenoxicam concentration (Cmax) was 4.3 mg.l-1 at a median tmax of 1.7 h.,The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),[mg] / [l],4.3,255618,DB00469,Tenoxicam
,1425878,tmax,The maximum tenoxicam concentration (Cmax) was 4.3 mg.l-1 at a median tmax of 1.7 h.,The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425878/),h,1.7,255619,DB00469,Tenoxicam
,3266152,elimination half-life,The elimination half-life of tenoxicam ranged from 44 to 132 h (mean 71.9 h) with no significant difference between the single and multiple dosage regimens.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),h,71.9,255927,DB00469,Tenoxicam
,3266152,maximum plasma concentrations,"Tenoxicam reached maximum plasma concentrations after 1.4 and 1.1 h, with values of 3.6 and 15.5 micrograms.",Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,3.6,255928,DB00469,Tenoxicam
,3266152,maximum plasma concentrations,"Tenoxicam reached maximum plasma concentrations after 1.4 and 1.1 h, with values of 3.6 and 15.5 micrograms.",Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,15.5,255929,DB00469,Tenoxicam
,3266152,trough,The corresponding trough values (24-h values) were 1.8 and 11.7 micrograms.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,1.8,255930,DB00469,Tenoxicam
,3266152,trough,The corresponding trough values (24-h values) were 1.8 and 11.7 micrograms.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),μg,11.7,255931,DB00469,Tenoxicam
,3266152,accumulation ratio,A mean accumulation ratio of 5.1 was calculated.,Single and multiple dose pharmacokinetics of tenoxicam in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3266152/),,5.1,255932,DB00469,Tenoxicam
,16169293,recoveries,"The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%.","Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169293/),%,78.3 to 87.1,268710,DB00469,Tenoxicam
,16169293,recoveries,"The recoveries of piroxicam, meloxicam and tenoxicam ranged from 78.3 to 87.1%, with that of isoxicam being 59.7%.","Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169293/),%,59.7,268711,DB00469,Tenoxicam
